Growth software: MongoDB breaks
Application software took the idiosyncratic hit. MongoDB (MDB) collapsed more than 20% after a weaker-than-expected full-year revenue outlook and a soft Q1 adjusted earnings forecast. This wasn’t “one quarter is ugly.” It was the reminder that the tape still punishes any hint of slower consumption, longer sales cycles, or budget friction when you’re wearing a growth multiple that assumes clean execution.
MDB became the session’s sentiment anchor. When a bellwether-style name resets guidance, positioning tightens without anyone needing a new Fed headline: the math gets harsher, investors demand more proof, and “durable” turns into “show me.” The repricing happened the old-fashioned way—via an air pocket and everyone rechecking their software exposure.
One smaller print: Semtech acquired HieFo for $34 million. A tuck-in for capability, not a balance-sheet event.
Biotech: Moderna clears the deck
Biotech had the cleaner catalyst. Moderna (MRNA) rose more than 10% after settling a patent dispute, removing an IP overhang that had been sitting on the stock.
For platform biotechs, legal clarity can move the distribution fast: take tail risk off the table and optionality gets valued again, even if next quarter’s fundamentals didn’t change overnight. Flows like certainty. Lawyers delivered it.
Consumer: execution wins
Retail was better, with the usual caveat: the market rewarded near-term execution more than long-range ambition.
- Ross Stores (ROST) moved higher after a strong start to the spring shopping season and raising its sales outlook. Value is still getting the traffic, and “better than feared” remains a tradable thesis when expectations are low.
- Best Buy (BBY) traded higher after earnings beat low expectations, despite weaker full-year sales guidance. The quarter cleared the bar, and investors leaned into the part of the story that supports a bounce.
- Target (TGT) was flat after outlining a $2 billion incremental investment plan aimed at 2% sales growth in 2026 via remodel acceleration and digital expansion. Credible, sure. Catalytic, no. Spend without near-term comp/margin proof is just a plan with a price tag.
Bottom line: consumer held up, but guidance discipline still runs the room.
Macro: oil, risk premium, a small housing offset
Macro pressure came through energy and geopolitics. Oil briefly touched $85/barrel as Iraqi production dropped and tanker traffic through the Strait of Hormuz declined sharply. That’s a physical-flow story: higher delivered-energy volatility, potential shipping/friction costs, and wider dispersion across equities. Energy bulls get a catalyst; most other sectors get another input cost and another thing to hedge.
The geopolitical premium widened after President Donald Trump signaled possible extended U.S. strikes on Iran and floated U.S. Navy escort of oil tankers. Markets care about duration here—how long disruptions last matters more than the first headline.
Housing was a modest offset. U.S. mortgage rates dipped below 6% before the Iran conflict began, supporting early spring home-buying activity. Not a trend signal, but even small rate relief can pull demand forward at the margin.
Positioning stayed twitchy. A sharp growth reset (MDB) plus escalation risk kept the de-risking impulse alive. Gold held up in flow terms even as a rising U.S. dollar and higher bond yields leaned on price—safe-haven demand doesn’t need a green close to show up.
What Mattered Today
- MDB -20% on a guide-down reset the tone for growth software.
- MRNA +10% on a patent settlement removed an overhang and lifted biotech sentiment.
- ROST/BBY got rewarded for execution versus a low bar; TGT offered spend plans, not a trigger.
- Oil to $85 and Iran/Hormuz headlines kept macro risk bid and positioning jumpy.
The session was simple: guidance and geopolitics did the driving, and nobody got paid for hoping.